연구동향 분석
박사

혈청 간효소 증가가 공복혈당장애 발생에 미치는 영향- 일개 제조업체 근로자들의 7년 추적관찰 연구 - = The Effects of Increased Serum Liver Enzymes on the Occurrence of Impaired Fasting Blood Glucose and Diabetes-7 years follow-up study of workers of a manufacturing company -

이미라 2015년

논문상세정보
인용/피인용
' 혈청 간효소 증가가 공복혈당장애 발생에 미치는 영향- 일개 제조업체 근로자들의 7년 추적관찰 연구 - = The Effects of Increased Serum Liver Enzymes on the Occurrence of Impaired Fasting Blood Glucose and Diabetes-7 years follow-up study of workers of a manufacturing company -' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 간기능
  • 공복혈당장애
  • 당뇨
  • 당뇨병
  • 혈당
  • 혈청간효소
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
418 0

0.0%

' 혈청 간효소 증가가 공복혈당장애 발생에 미치는 영향- 일개 제조업체 근로자들의 7년 추적관찰 연구 - = The Effects of Increased Serum Liver Enzymes on the Occurrence of Impaired Fasting Blood Glucose and Diabetes-7 years follow-up study of workers of a manufacturing company -' 의 참고문헌

  • 혈청 감마지티와 당뇨병 유병률과의 상관관계
  • 한국 당뇨병에 대한 보고서
    대한당뇨병학회 [2012]
  • 지역 중년 및 노인에서의 혈청 감마지티피와 공복혈당장애의 유병률과의 상관관계
  • 전국표본조사에 의한 우리나라 당뇨병 관리실태: 건강보험 자료 분석결과
  • 만성 간질환과 당뇨병
    김보완 대한내과학회지, 57(3): 269-272 [1999]
  • 대사증후군 예측인자로서 알라닌아미노전이효소의 의미
    강양호 권지혜 김용기 김인주 손석만 안용성 대한내분비학회지, 23(6): 404-412 [2008]
  • 당뇨병의 조기 진단과 검사법
    손현식 대한의사협회지, 51(9): 813-817 [2008]
  • 간기능검사, 연세대학교 의과대학교 내과학 교실
    김도영 대한내과학회 춘계 학술발표논문집, 5-11 [2014]
  • 간기능 검사의 이해와 적용
    김경아 대한내과학회지, 76(2): 163-168 [2009]
  • Zimmet P: Globalization, coca-colonization and the chronic disease epidemic: can the Doomsday scenario be averted? J Intern Med, 247: 301-310, 2000.
  • Yokoyama H, Hirose H, Moriya S, Saito I. Significant correlation between insulin resistance and serum gamma-glutamyltranspeptidase (gamma-GTP) activity in non-drinkers. Alcohol Clin Exp Res, 26: 91S-94S, 2002.
  • Wei M, Gaskill SP, Haffner SM, Stern MP: Waist circumference as the best predictor of noninsulin dependent diabetes mellitus (NIDDM) compared to body mass index, waist/hip ratio and other anthropometric measurements in Mexican Americans--a 7-years prospective study. Obes Res 5: 16-23, 1997.
  • Wannamethee G, Ebrahim S, Shaper AG: Gamma-glutamyltransferase: determinants and association with mortality from ischemic heart disease and all causes. Am J Epidemiol, 142: 699-708, 1995.
  • Takahashi Y, Oakes SM, Williams MC, Takahashi S, Miura T, Joyce-Brady M. Nitrogen dioxide exposure activates gammaglutamyl transferase gene expression in rat lung. Toxicol Appl Pharmacol, 143: 388-396, 1997.
  • Stevens J, Couper D, Pankow J, Folsom AR, Duncan BB, Nieto FJ, Jones D, Tyroler HA: Sensitivity and specificity of anthropometrics for the prediction of diabetes in a biracial cohort. Obes Res 9: 696-705, 2001.
  • Sattar N, Scherbakova O, Ford I, O’Reilly DS, Stanley A, Forrest E, et al. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes, 53: 2855-2860, 2004.
  • Retrieved September 17 2014, from http://sis.nhis.or.kr/site/sis/ggoz103m01?#38;open_main=1&open_sub1=1&open_sub2=0
  • Rantala AO, Lilja M, Kauma H, Savolainen MJ, Reunanen A, Kesaniemi YA. Gamma-glutamyl transpeptidase and the metabolic syndrome. J Intern Med, 248: 230-238, 2000.
  • Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2 86: 327-334, 2001.
  • Pintus F, Mascia P. Distribution and population determinants of gamma-glutamyltransferase in a random sample of Sardinian inhabitants. ATS-SARDEGNA’ Research Group. Eur J Epidemiol, 12: 71-76, 1996.
  • Perry IJ, Wannamethee SG, Shaper AG. Prospective study of serum gamma-glutamyltransferase and risk of NIDDM. Diabetes Care, 21: 732-737, 1998.
  • Ortega E, Koska J, Salbe AD, Tataranni PA, Bunt JC. Serum gamma-glutamyl transpeptidase is a determinant of insulin resistance independently of adiposity in Pima Indian children. J Clin Endocrinol Metab, 91: 1419-1422, 2006.
  • Nilssen O, F rde OH, Brenn T. The Troms Study. Distribution and population determinants of gamma-glutamyltransferase. Am J Epidemiol, 132: 318-326, 1990.
  • National Health Insurance Service (2013),
  • National Health Insurance Agency(NHIA). (2013). 2011 National health screening statistical yearsbook. Seoul: National Health Insurance Agency.
  • Nannipieri M, Gonzales C, Baldi S, Posadas R, Williams K, Haffner SM, Stern MP, Ferrannini E:Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study. Diabetes Care, 28: 1757-1762, 2005.
  • Nakanishi N, Suzuki K, Tatara K. Serum gamma-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men. Diabetes Care, 27: 1427-1432, 2004.
  • Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes, 50: 1844-1850, 2001.
  • Levitan EB, Song Y, Ford ES, Liu S. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med, 164: 2147-1255, 2004.
  • Lee, DH., Blomhoff, R., & Jacobs, D. R. (2004). Is serum gamma glutamyltransferase a marker of oxidative stress? Free Radical Research, 38(6): 535-539, 2004.
  • Lee DH, Silventoinen K, Jacobs DR Jr, Jousilahti P, Tuomileto J. Gamma-Glutamyltransferase, obesity, and the risk of type 2 diabetes: observational cohort study among 20,158 middle-aged men and women. J Clin Endocrinol Metab, 89: 5410-5414, 2004.
  • Lee DH, Lee IK, Song K, Steffes M, Toscano W, Baker BA, et al. A strong dose-response relation between serum concentrations of persistent organic pollutants and diabetes: results from the National Health and Examination Survey 1999-2002. Diabetes Care, 29: 1638-1644, 2006.
  • Lee DH, Jacobs DR Jr, Gross M, Kiefe CI, Roseman J, Lewis CE, et al. Gamma-glutamyltransferase is a predictor of incident diabetes and hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clin Chem, 49(13): 58-66, 2003b.
  • Lee DH, Ha MH, Kim JH, Christiani DC, Gross MD, Steffes M, et al. Gamma-glutamyltransferase and diabetes: a 4 years followup study. Diabetologia, 46: 359-364, 2003a.
  • King H, Aubert RE, Herman WH: Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care, 21: 1414-1431, 1998.
  • Kim DJ, Noh JH, Cho NH, Lee BW, Cho NHi YH, Jung JH, Min YK, Lee MS, Lee MK, Kim KW: Serum gamma -glutamyltransferase within its normal concentration range is related to the presence of diabetes andcardiovascular risk factors. Diabet Med, 22: 1134-1140, 2005.
  • Karp DR, Shimooku K, Lipsky PE. Expression of gammaglutamyl transpeptidase protects ramos B cells from oxidationinduced cell death. J Biol Chem, 276: 3798-3804, 2001.
  • International Diabetes Federation. The diabetes atlas. 5th ed. Brussels: International Diabetes Federation; 2011.
  • Health examination implementation guidelines: No. 2013-61
  • Hanley AJ, Williams K, Festa A, Wagenknecht LE, D’Agostino RB Jr, Kempf J, et al. Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes, 53: 2623-2632, 2004.
  • Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD, et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes, 51: 1596-1600, 2002.
  • Diabetes Care. 2014 Jan;37 Suppl 1:S14-80. doi: 10.2337/dc14-S014.
  • Diabetes Care, Jan: 37 Suppl 1:S14-80. doi: 10.2337/dc14-S014, 2014.
  • Cho NH, Lee HK, Jang HC, Chan JCN, Cho NHi SH, Lim S, Kim HR: Abnormal liver function test predicts type 2 diabetes. Diabetes Care , 30: 2566-2568, 2007.
  • Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol, 24: 816-823, 2004.
  • Carlisle ML, King MR, Karp DR. Gamma-glutamyl transpeptidase activity alters the T cell response to oxidative stress and Fas-induced apoptosis. Int Immunol, 15: 17-27, 2003.
  • Campos SP, Baumann H: Insulin is a prominent modulator of the cytokine-stimulated expression of acute-phase plasma protein genes. Mol Cell Biol, 12: 1789-1797, 1992.
  • Andre P, Balkau B, Born C, Charles MA, Eschwege E: Three-years increase of gamma-glutamyltransferase level and development of type 2 diabetes in middle -aged men and women: the D.E.S.I.R. cohort. Diabetologia, 49: 2599-2603, 2006.
  • American Diabetes Association.Standards of medical care in diabetes-2014.